1,333 research outputs found
Less Talk, More Walk: Strengthening Homeland Security Now
No full textAuthor David Isenberg, an independent consultant on defense and security affairs, analyzes the defense of the U.S. homeland, in this new CDI publication. Preparedness, planning, organizational changes, communications and weapons of mass destruction are some of the many issues that are examined. Isenberg concludes there is plenty for Congress to do, and not enough immediate funding available. Executive Summary is available in Adobe Acrobat format by clicking on the link below
Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity
No full textWhen purified under rigorous conditions, some murine anti-double-stranded-DNA (anti-dsDNA) antibodies actually bind chromatin rather than dsDNA. This suggests that they may actually be antinucleosome antibodies that only appear to bind dsDNA when they are incompletely dissociated from nucleosomes. Experiments in murine models suggest that antibody - nucleosome complexes may play a crucial role in the pathogenesis of glomerulonephritis in systemic lupus erythematosus. Some human monoclonal anti- DNA antibodies are pathogenic when administered to mice with severe combined immunodeficiency (SCID). Our objective was to achieve stable expression of sequence-altered variants of one such antibody, B3, in Chinese hamster ovary (CHO) cells. Purified antibodies secreted by these cells were tested to investigate whether B3 is actually an antinucleosome antibody
The Wolff Family of Muenstereifel.
No full textThe following individuals are mentioned in this manuscript:Adelheid, Emma; Bromet, Eva; Gottschalk, August; Gottschalk, Caroline; Gottschalk, Jedula; Heilbron, Max; Heilbronn, Ille; Heiman, Edgar; Heiman, Freddy; Heiman, Julehen; Herman, David; Horn, Eduard; Horn, Ernestine Sofia; Horn, Lutz; Horn, Rosad; Isenberg, Janet Bernd; Isaac, Else; Katz, Margo; Orfinger, Lucien; Orfinger, Pierre Nenette; Raber, Dan; Voss, Rosalie; Wolff, Abraham; Wolff, Adelheid; Wolff, Aron; Wolff, Benjamin; Wolff, Bernhard; Wolff, Berta; Wolff, Clara; Wolff, David; Wolff, Eva; Wolff, Heinrich; Wolff, Hugo; Wolff, Judula; Wolff, Moses; Wolff, Rosalie; Wolff, Simon; Wolff, Susmann.Synopsis in file
Biologic treatments for idiopathic inflammatory myopathies
No full textThe idiopathic inflammatory myopathies are a group of acquired, heterogeneous, systemic diseases of skeletal muscle. As these conditions are uncommon, current treatment of myositis is based mainly on case reports and few randomised studies with small numbers of patients enrolled. Therefore, the current treatment paradigm is still relies primarily on clinical experience. High dose corticosteroids continue to be the first line therapy. In order to avoid side effects, the prednisolone dose should be reduced based on patient’s clinical response. Other immunosuppressive drugs are used in refractory cases, as well as steroid-sparing agents. Nevertheless, a Cochrane review concluded that there was insufficient evidence from the available studies to confirm the value of immunosuppressive agents in myositis. In patients with myositis resistant to conventional treatment, rituximab is a potential treatment option. Several agents could be of interest for future studies of myositis treatment; however more randomised controlled trials are needed to identify eligibility criteria, outcome predictors and the adequate regimen. The identification of responsive patients and specific therapies targeting the correct myositis subset may be cost-effective and potentially prevent incorrect use of biologics
<b>Supplemental Material - Predictors of British Isles Lupus Assessment Group-based outcomes in patients with systemic lupus erythematosus: Analysis from the Systemic Lupus International Collaborating Clinics Inception Cohort</b>
No full textSupplemental Material for Predictors of British Isles Lupus Assessment Group-based outcomes in patients with systemic lupus erythematosus: Analysis from the Systemic Lupus International Collaborating Clinics Inception Cohort by Trixy David, Li Su, Yafeng Cheng, Caroline Gordon, Benjamin Parker, David Isenberg, John A Reynolds, Ian N Bruce, on behalf of the Systemic Lupus International Collaborating Clinics Consortium and MASTERPLANS Consortium in Lupus.</p
Three Benchmark Datasets for Scholarly Article Layout Analysis
No full textDatasetThis dataset contains three benchmark datasets as part of the scholarly output of and ICDAR 2021 paper: Meng Ling, Jian Chen, Torsten Moller, Petra Isenberg, Tobias Isenberg, Michael Sedlmair, Robert S. Laramee, Han-Wei Shen, Jian Wu, and C. Lee Giles, Document Domain Randomization for Deep Learning Document Layout Extraction, 16th International Conference on Document Analysis and Recognition (ICDAR) 2021. September 5-10, Lausanne, Switzerland. This dataset contains nine class labels: abstract, algorithm, author, body text, caption, equation, figure, table, and title
Existence, uniqueness and other properties of the BCT (minimal strain lapse and shift) gauge
No full textBrady, Creighton and Thorne (BCT) have proposed a choice of the lapse and shift for numerical evolutions in general relativity that extremizes a measure of the rate of change of the 3-metric (BCT gauge). We investigate the existence and uniqueness of this gauge (with Dirichlet boundary conditions), and comment on its use in numerical time evolutions
Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
No full textSystemic lupus erythematosus (SLE) is an autoimmune disease with a complex pathogenesis, which presents a great variability in its presentation and can affect almost all organs and systems. Multiple therapeutic targets have been discovered recently, but there also have been failed attempts to treat SLE using biologic agents. Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase expressed in several types of cells of hematopoietic origin which participate in both innate and adaptive immunity. Ibrutinib, a BTK inhibitor, is approved for the treatment of several B cell malignancies, including some types of lymphoma and leukemia. As BTK is expressed on several immune cell types, the mechanism of action of BTK also suggests the use of BTK inhibitors in the treatment of autoimmune diseases. In this review, we will summarize what is known and what has been published so far about the treatment of mouse models of SLE and the human disease, using BTK inhibitors
- …
